نتائج البحث

High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.

• Authors : Wang EH; Cancer Center, University of California, San Diego, California, USA.; Chen YA

Subjects: Hematopoietic Stem Cell Transplantation*; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*administration & dosage ; Carmustine/Carmustine/Carmustine/*administration & dosage BEAM protocol

• Source: Bone marrow transplantation [Bone Marrow Transplant] 2004 Oct; Vol. 34 (7), pp. 581-7.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print Cited Medium: Print ISSN: 0268-3369

تفاصيل العنوان

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

• Source: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin

تفاصيل العنوان

Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.

• Authors : Reid RM; James P Wilmot Cancer Institute and Department of Medicine, University of Rochester Medical Center, Rochester, New York.; Rochester Regional Health, Rochester, New York.

Subjects: Hematopoietic Stem Cell Transplantation*/Hematopoietic Stem Cell Transplantation*/Hematopoietic Stem Cell Transplantation*/adverse effects ; Hematopoietic Stem Cell Transplantation*/Hematopoietic Stem Cell Transplantation*/Hematopoietic Stem Cell Transplantation*/methods ; Transplantation Conditioning*/Transplantation Conditioning*/Transplantation Conditioning*/adverse effects BEAM protocol

• Source: Cancer medicine [Cancer Med] 2016 Nov; Vol. 5 (11), pp. 3059-3067. Date of Electronic Publication: 2016 Oct 03.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

• Source: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell

تفاصيل العنوان

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE As Salvage Therapy for Transplant Eligible Patients with Relapsed/ Refractory Large B-Cell Lymphoma

• Authors : David Bond, MD, Principal Investigator

• Source: A Phase II Trial of Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE As Salvage Therapy for Transplant Eligible Patients with Relapsed/ Refractory Large B-Cell

تفاصيل العنوان

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

• Source: Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing LymphomasRutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N,

تفاصيل العنوان

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

• Source: Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

تفاصيل العنوان

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

• Authors : Bristol-Myers Squibb; David Bond, MD, Principal Investigator

• Source: A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

تفاصيل العنوان

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

• Source: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic

تفاصيل العنوان

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

• Source: A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young AdultsCastellino

تفاصيل العنوان